Related Experiment Video
Updated: Jul 4, 2025
07:30
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
9.3K
Challenges of insulin-like growth factor-1 testing
Rongrong Huang1,2, Junyan Shi3,4, Ruhan Wei5
1Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX, USA.
Critical Reviews in Clinical Laboratory Sciences
|February 7, 2024
Summary
Accurate Insulin-like Growth Factor 1 (IGF-1) measurement is crucial for diagnosing growth disorders. Mass spectrometry offers a more reliable method than traditional immunoassays, improving diagnostic specificity and sensitivity.
Area of Science:
- Endocrinology
- Clinical Chemistry
- Biochemistry
Background:
- Insulin-like Growth Factor 1 (IGF-1) is a key regulator of growth hormone (GH) actions, influencing cell proliferation, differentiation, and apoptosis.
- IGF-1 has a longer half-life than GH, making its measurement more specific and sensitive for diagnosing conditions like acromegaly and GH deficiency.
- IGF-1 immunoassays are susceptible to interference from IGF-binding proteins (IGFBPs) and variants, leading to inaccurate results.
Purpose of the Study:
- To review the challenges in standardizing IGF-1 measurement methods.
- To discuss techniques for minimizing pre-analytical factors and harmonizing IGF-1 reference intervals.
- To highlight the development and advantages of mass spectrometric methods for IGF-1 quantification.
Main Methods:
- Review of existing literature on IGF-1 measurement techniques.
- Analysis of the impact of pre-analytical factors and IGFBPs on assay accuracy.
- Examination of mass spectrometric approaches ('top-down' and 'bottom-up') for IGF-1 quantification.
Main Results:
- Mass spectrometry provides robust, reliable, and accurate IGF-1 quantification by minimizing interference from IGF-1 variants.
- Mass spectrometry enables potential detection of pathogenic mutations through protein sequence analysis.
- Discordance in IGF-1 reference intervals stems from various factors, necessitating standardization and multicenter collaboration.
Conclusions:
- Standardization of IGF-1 measurement methods, minimization of pre-analytical variability, and harmonization of reference intervals are critical for accurate clinical interpretation.
- Mass spectrometry represents a significant advancement in IGF-1 measurement, offering superior accuracy and reliability over traditional immunoassays.
- Collaborative efforts among laboratorians, clinicians, and manufacturers are essential for establishing cost-effective and resource-efficient IGF-1 reference intervals nationwide.
Related Concept Videos
01:16Insulin: Dosing Regimen and Adverse Effects
174
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
174
01:28Insulin: The Receptor and Signaling Pathways
1.2K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.2K